Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol
about
The benzodiazepine binding site of GABA A receptors as a target for the development of novel anxiolyticsBiomarkers for the effects of benzodiazepines in healthy volunteersAnxioselective anxiolytics: on a quest for the Holy Grail50 years of hurdles and hope in anxiolytic drug discoverySelective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator.Superadditive effects of ethanol and flunitrazepam: implications of using immunopharmacotherapy as a therapeutic.Toxicological interactions between alcohol and benzodiazepines.Pharmacodynamic interactions of a solid formulation of sodium oxybate and ethanol in healthy volunteers.A comparative study of two methods for attaining constant alcohol levelsCentral nervous system effects of alcohol at a pseudo-steady-state concentration using alcohol clamping in healthy volunteers.The inhibitory GABA system as a therapeutic target for cognitive symptoms in schizophrenia: investigational agents in the pipeline.The effects of fall-risk-increasing drugs on postural control: a literature review.Pharmacokinetic and pharmacodynamic drug interactions with ethanol (alcohol).GABA(A)-receptor subtypes: clinical efficacy and selectivity of benzodiazepine site ligands.Differential effects of the dual orexin receptor antagonist almorexant and the GABA(A)-α1 receptor modulator zolpidem, alone or combined with ethanol, on motor performance in the rat.The central nervous system effects of the partial GABA-Aα2,3 -selective receptor modulator AZD7325 in comparison with lorazepam in healthy males.The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects.Placebo- and amitriptyline-controlled evaluation of central nervous system effects of the NK1 receptor antagonist aprepitant and intravenous alcohol infusion at pseudo-steady state.alpha2-gamma-Aminobutyric acid (GABA)A receptors are the molecular substrates mediating precipitation of narcosis but not of sedation by the combined use of diazepam and alcohol in vivo.Pharmacology in translation; the preclinical and early clinical profile of the novel α2/3 functionally selective GABAA receptor positive allosteric modulator PF-06372865.Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol.The mouse beam walking assay offers improved sensitivity over the mouse rotarod in determining motor coordination deficits induced by benzodiazepines.Pharmacokinetics and pharmacodynamics of a new highly concentrated intranasal midazolam formulation for conscious sedation.Pharmacodynamic response profiles of anxiolytic and sedative drugs.Ethanol impairs saccadic and smooth pursuit eye movements without producing self-reports of sedation.The effects of TPA023, a GABAAα2,3 subtype-selective partial agonist, on essential tremor in comparison to alcohol.
P2860
Q22306024-B96820FB-2700-4BED-A84F-3FEF76CF2FF7Q24679523-A9D3B574-28D4-432E-8D2D-E444D35A8024Q28275122-E485856E-EB6F-457F-A9B8-B13708015AC7Q28297569-EF7FBC80-F420-4C8A-8D98-A8DD861AD661Q28972575-1CA27F9F-BE37-4DD4-9D38-70533C1B36E4Q34384750-35AC6C5B-2164-4F36-B1CE-B8746E84E3D1Q34624505-B74585B8-C8AA-47E7-B2AE-CE28ECC27B57Q36072485-DE26FF99-EF36-4D03-AB13-5BB85480A3B5Q37142448-A0125B11-0639-4779-8EE1-8290D7A2B8B8Q37427922-B2016ABE-D2E3-433F-BD9E-632FA3EFF664Q37784829-BA8FED8A-E927-4E84-ABAA-1E957D849BCBQ38134320-7E8C1ACF-8534-41A5-A9B7-8EF2B2C76DB5Q38255420-15F19A46-EE3B-4B23-8768-E74976BFCDEFQ41647720-0F3A27CB-CE70-44D9-AF1C-0FCD927C425DQ41965748-1419FACC-8F31-4691-AF01-789D79EA0765Q42283018-B0F9DE22-882F-4D17-9051-F17146D83967Q43168345-8873DC36-2F03-4AC3-A1C3-FA0CBD0B292FQ44254954-8B7E3593-97DE-4BAE-A56E-658C2DC2A358Q44658144-926723E7-A077-46DC-8719-9A0E9E6EC6AEQ46246232-26B5BAB5-F7E8-4805-BAEB-5DB19C661FFEQ46404900-F045CA72-0FFC-4D32-8E4D-2D8DB5B03979Q46486014-2E3C8F2A-AE0D-49B0-B8E8-73547FEF899AQ47373267-1D1A5006-483C-44F3-9759-1DF19F6C291EQ48178645-7516AA2A-152C-4C48-875E-78F38152F65CQ48217471-8F534D06-8971-474D-9D5F-1B0CC9633F34Q50262795-A72114FC-FFF1-46E4-802B-E1EA4AFAD7E7
P2860
Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol
description
1996 nî lūn-bûn
@nan
1996 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol
@ast
Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol
@en
Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol
@nl
type
label
Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol
@ast
Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol
@en
Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol
@nl
prefLabel
Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol
@ast
Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol
@en
Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol
@nl
P2093
P921
P1476
Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol
@en
P2093
A L van Steveninck
D D Breimer
M S Pieters
R C Schoemaker
R Gieschke
P304
P356
10.1046/J.1365-2125.1996.38514.X
P407
P577
1996-06-01T00:00:00Z